^
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
trametinib + dabrafenib
Sensitive: A1 - Approval
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
dabrafenib
Sensitive: A1 - Approval
No biomarker
Thyroid Gland Anaplastic Carcinoma
CaT
Sensitive: A2 - Guideline
No biomarker
Thyroid Gland Anaplastic Carcinoma
cisplatin
Sensitive: A2 - Guideline
No biomarker
Thyroid Gland Anaplastic Carcinoma
docetaxel + doxorubicin hydrochloride
Sensitive: A2 - Guideline
No biomarker
Thyroid Gland Anaplastic Carcinoma
doxorubicin hydrochloride
Sensitive: A2 - Guideline
No biomarker
Thyroid Gland Anaplastic Carcinoma
paclitaxel
Sensitive: A2 - Guideline
NTRK3 fusion
Thyroid Gland Anaplastic Carcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Thyroid Gland Anaplastic Carcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Thyroid Gland Anaplastic Carcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Thyroid Gland Anaplastic Carcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Thyroid Gland Anaplastic Carcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Thyroid Gland Anaplastic Carcinoma
larotrectinib
Sensitive: A2 - Guideline
RET mutation
Thyroid Gland Anaplastic Carcinoma
selpercatinib
Sensitive: A2 - Guideline
TMB-H
Thyroid Gland Anaplastic Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Thyroid Gland Anaplastic Carcinoma
carboplatin + paclitaxel
Sensitive: A2 - Guideline
RET fusion
Thyroid Gland Anaplastic Carcinoma
pralsetinib
Sensitive: A2 - Guideline
No biomarker
Thyroid Gland Anaplastic Carcinoma
AIC100
Sensitive: B - Late Trials
EGFR L858R
Thyroid Gland Anaplastic Carcinoma
erlotinib
Sensitive: C1 - Off-label
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
vemurafenib
Resistant: C1 - Off-label
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
atezolizumab + cobimetinib
Sensitive: C2 – Inclusion Criteria
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
trametinib + dabrafenib
Sensitive: C2 – Inclusion Criteria
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
PLX8394 + cobicistat
Sensitive: C3 – Early Trials
PD-L1 overexpression
Thyroid Gland Anaplastic Carcinoma
pembrolizumab + lenvatinib
Sensitive: C3 – Early Trials
TMB-H
Thyroid Gland Anaplastic Carcinoma
pembrolizumab + lenvatinib
Sensitive: C3 – Early Trials
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
vemurafenib + atezolizumab
Sensitive: C3 – Early Trials
NF1 mutation
Thyroid Gland Anaplastic Carcinoma
atezolizumab + cobimetinib
Sensitive: C3 – Early Trials
KRAS mutation
Thyroid Gland Anaplastic Carcinoma
atezolizumab + cobimetinib
Sensitive: C3 – Early Trials
HRAS mutation
Thyroid Gland Anaplastic Carcinoma
atezolizumab + cobimetinib
Sensitive: C3 – Early Trials
NF2 mutation
Thyroid Gland Anaplastic Carcinoma
atezolizumab + cobimetinib
Sensitive: C3 – Early Trials
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
BRAF inhibitor
Sensitive: C3 – Early Trials
NTRK3 positive
Thyroid Gland Anaplastic Carcinoma
larotrectinib
Sensitive: C3 – Early Trials
NTRK2 positive
Thyroid Gland Anaplastic Carcinoma
larotrectinib
Sensitive: C3 – Early Trials
NTRK1 positive
Thyroid Gland Anaplastic Carcinoma
larotrectinib
Sensitive: C3 – Early Trials
BRAF V600E + PD-L1 expression
Thyroid Gland Anaplastic Carcinoma
nivolumab + vemurafenib
Sensitive: C4 – Case Studies
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
trametinib + dabrafenib + everolimus
Sensitive: C4 – Case Studies
ALK1 overexpression
Thyroid Gland Anaplastic Carcinoma
crizotinib
Sensitive: C4 – Case Studies
ALK1 rearrangement
Thyroid Gland Anaplastic Carcinoma
crizotinib
Sensitive: C4 – Case Studies
MTOR F2108L
Thyroid Gland Anaplastic Carcinoma
everolimus
Resistant: C4 – Case Studies
TSC2 Q1178X
Thyroid Gland Anaplastic Carcinoma
everolimus
Resistant: C4 – Case Studies
PIK3CA H1047R
Thyroid Gland Anaplastic Carcinoma
trametinib + dabrafenib + everolimus
Sensitive: C4 – Case Studies
CCDC6-RET fusion
Thyroid Gland Anaplastic Carcinoma
selpercatinib
Sensitive: C4 – Case Studies
PD-L1 negative + TMB-L
Thyroid Gland Anaplastic Carcinoma
anlotinib + sintilimab
Sensitive: C4 – Case Studies
PD-L1 overexpression
Thyroid Gland Anaplastic Carcinoma
anlotinib + sintilimab
Sensitive: C4 – Case Studies
BRAF V600E + TERT E441del + RET N579K + EZH2 D154E + CDK4 S259L
Thyroid Gland Anaplastic Carcinoma
dabrafenib + SNR1611
Sensitive: C4 – Case Studies
HRAS Q61R + TP53 P278S + PD-L1 overexpression
Thyroid Gland Anaplastic Carcinoma
rivoceranib + camrelizumab
Sensitive: C4 – Case Studies
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
dabrafenib + SCH772984
Sensitive: D – Preclinical
HRAS G13R
Thyroid Gland Anaplastic Carcinoma
MK-2206
Sensitive: D – Preclinical
NRAS Q61R
Thyroid Gland Anaplastic Carcinoma
MK-2206
Sensitive: D – Preclinical
PIK3CA H1047R
Thyroid Gland Anaplastic Carcinoma
MK-2206
Sensitive: D – Preclinical
HRAS G13R
Thyroid Gland Anaplastic Carcinoma
CI-1040
Sensitive: D – Preclinical
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
sorafenib
Sensitive: D – Preclinical
CASP12 overexpression
Thyroid Gland Anaplastic Carcinoma
carboplatin
Sensitive: D – Preclinical
CYCS overexpression
Thyroid Gland Anaplastic Carcinoma
carboplatin
Sensitive: D – Preclinical
CASP8 overexpression
Thyroid Gland Anaplastic Carcinoma
carboplatin
Sensitive: D – Preclinical
CASP3 overexpression
Thyroid Gland Anaplastic Carcinoma
carboplatin
Sensitive: D – Preclinical
KRAS G12R
Thyroid Gland Anaplastic Carcinoma
GSKJ4
Sensitive: D – Preclinical
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
trametinib + dabrafenib + AZD1775
Sensitive: D – Preclinical